The CEOs of three major pharmaceutical companies defended the need for reforming pharmacy benefit manager practices during the recent Senate hearing on drug pricing, but they also implied current legislation is not enough to drive lower list prices.
The message from Johnson & Johnson CEO Joaquin Duato, Bristol Myers Squibb Company CEO Chris Boerner and







